• barrier membranes;
  • enamel matrix proteins;
  • GTR;
  • intra-osseous defects;
  • tetracycline


Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel®) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex®).

Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.

Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86±0.75 mm, a mean gain in CAL of 1.28±2.04 mm, a mean PBL gain of 1.63±1.21 mm and a mean increase of recession (REC) of 1.56±2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02±1.55 mm, a mean gain in CAL of 1.65±1.29 mm, a mean PBL gain of 1.58±1.92 mm and a mean increase of REC of 1.38±1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.

Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.